What people say about IMPACTT

Patients, parents and investigators tell why IMPACTT is important for them.

“As parents of a CF child we think this study is extremely important!  We really hope they will find solutions to prevent and treat pseudomonas more effectively”

“By participating in such clinical trials we can really contribute in research and help to find solutions for fighting pseudomonas.”

“If you can’t prevent and control pseudomonas, you need a intravenous treatment every 3 months, what a waste of time and money! ... Reasons enough to INVEST in research and TO PARTICIPATE!”

“IgY has the potential to delay or even prevent pseudomonas infection. Thus burden might be kept away from patients' lives for a longer time than it is possible today. That is such an exciting prospect! “

“I  want to thank all who strive to make cli IgY-research a success.”

If we find a way to prevent infection with Pseudomonas aeruginosa, this will be a huge step forward in CF management. We hope that IMPACTT will help us to reach that goal.”

“As parents of a CF child we think this study is extremely important!  We really hope they will find solutions to prevent and treat pseudomonas more effectively.  If we could get rid of this germ rapidly, we could prevent chronic infection and decline in lung function.  By participating in such clinical trials you can really contribute in research and help to find solutions for fighting pseudomonas.”
Mother of a CF Child

 

“If you can’t prevent and control pseudomonas, you need a intravenous treatment every 3 months, what a waste of time and money! And you ‘simply’ feel much worse if you have pseudomonas in your lungs... Reasons enough to INVEST in research and TO PARTICIPATE!”
E, CF patient, 25 years

 

“I am a patient who was born in the fifties of the last century. In those days there was no therapy at all. Today there are new CF drugs under development which will make a big difference in quality of life and life expectancy. IgY has the potentiality to delay or even prevent pseudomonas infection. Thus burden might be kept away from patients' lives for a longer time than it is possible today. That is such an exciting prospect! I want to thank all who strive to make IgY a success.”
 

Anni Brunckhorst, CF adult

 

“If we find a way to prevent infection with Pseudomonas aeruginosa, this will be a huge step forward in CF management. We hope that IMPACTT will help us to reach that goal.”


Prof. Schuster, IMPACTT Coordinating investigator